Otsuka Pharmaceutical Development & Commercialization, Inc.
Rockville, MD
- UEI
- N4TCZ8N86B21
- CAGE
- 7ZLN3
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2440 Research Blvd, Rockville, MD 20850, USA
- Website
- otsuka-us.com
- Founded
- 1921
- Employees
- 10K-50K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Brexpiprazole as an adjunctive treatment to buprenorphine to treat opioid use disorder | National Institute on Drug Abuse (NIH) | $4,023,155 |
Quick answers
Is Otsuka Pharmaceutical Development & Commercialization, Inc. registered in SAM.gov?
Yes. Otsuka Pharmaceutical Development & Commercialization, Inc.'s SAM.gov registration is active through August 15, 2027.
What is Otsuka Pharmaceutical Development & Commercialization, Inc.'s most recent federal award?
Otsuka Pharmaceutical Development & Commercialization, Inc.'s most recent federal grant award is Brexpiprazole as an adjunctive treatment to buprenorphine to treat opioid use disorder (UG3DA051383), from National Institute on Drug Abuse (NIH), on September 30, 2020.
On GovTribe
See Otsuka Pharmaceutical Development & Commercialization, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors